In a report released today, Chris Shibutani from Goldman Sachs maintained a Hold rating on Entrada Therapeutics Inc (TRDA – Research Report). The company’s shares closed today at $14.89.
According to TipRanks, Shibutani is a 5-star analyst with an average return of 21.9% and a 45.45% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as BioNTech SE, Alkermes, and Bristol-Myers Squibb.
Entrada Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
See today’s best-performing stocks on TipRanks >>
Based on Entrada Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $25.26 million and a GAAP net loss of $6.67 million. In comparison, last year the company had a GAAP net loss of $21.67 million
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TRDA in relation to earlier this year. Most recently, in June 2023, WENTWORTH KORY JAMES, the CFO of TRDA bought 8,790.00 shares for a total of $18,459.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Read More on TRDA:
